#ESMO26 🧬 COMPANION-002 | Phase III
👥 Previously treated BTC
💊 Paclitaxel + tovecimig vs paclitaxel
🎯 ORR: 18% vs 5.3%
📈 mPFS: 4.7 vs 2.6 mo
⏳ mOS: 8.9 vs 9.4 mo
❌ No OS benefit despite improved ORR & PFS.
💡 Promising activity, but not a new SoC
@OncoAlert
15 views · 0 likes · 0 reposts · 0 replies
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.orgSource: Nieves Martinez Lago MD PhD · x.com